Cardiologists who study gene therapy explain its promise, risks and the safeguards needed for responsible use. Early successes in gene therapy have focused on these rare disorders, such as spinal muscular atrophy and sickle cell disease. Gene therapy is no longer the future of medicine — it’s reality. Treatments that replace, silence or edit genes are already changing clinical care. There are more than 6,000 rare genetic disorders but only a fraction currently have treatable targets. Current gene therapies target somatic cells, meaning any genetic changes are not intended to be passed to future generations. Murthy: For rare, severe diseases, the case can be relatively straightforward: The unmet need is high, and patients may have few or no effective alternatives. Some currently available gene therapies have list prices exceeding $1 million per patient, with several priced substantially higher. While a one-time therapy may make sense for a rare, life-threatening disease, similar pricing models would be difficult to sustain for conditions affecting millions of people.

Gene therapy is no longer the future of medicine - it's reality. Treatments that replace, silence or edit genes are already changing clinical care. Gene therapy is no longer the future of medicine - it's reality. Treatments that replace, silence or edit genes are already changing clinical care. There are more than 6,000 rare genetic disorders but only a fraction currently have treatable targets. Early successes in gene therapy have focused on these rare disorders, such as spinal muscular atrophy and sickle cell disease. Current gene therapies target somatic cells, meaning any genetic changes are not intended to be passed to future generations. Murthy: For rare, severe diseases, the case can be relatively straightforward: The unmet need is high, and patients may have few or no effective alternatives. New SPARCS technology combines AI and microscopy to screen cells · CRISPR activation library uncovers gene driving lymphoma growth and resistance · The calculation becomes more complex for common conditions, where genomic therapies may compete with treatments that already work well and can be adjusted or stopped if problems arise. At the population level, even extremely rare side effects could affect large numbers of people if millions receive treatment.